Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if giving CAMPATH-1H with rituximab can
shrink or slow the growth of the disease in patients with chronic lymphoid disorders that
have either not responded or whose disease has returned after treatment with standard
therapies.